{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:16:05Z","timestamp":1774548965207,"version":"3.50.1"},"reference-count":128,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01366","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T04:43:32Z","timestamp":1575607412000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":65,"title":["The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Gerard J.","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico","family":"van Zandwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E. J.","family":"Rasko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the Consensus Statement From the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211416","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"8565","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","article-title":"Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM)","volume":"36","author":"Desai","year":"2018","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.091","article-title":"LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1743-8977-7-5","article-title":"Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma","volume":"7","author":"Donaldson","year":"2010","journal-title":"Part Fibre Toxicol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/019021400404528","article-title":"Asbestos exposure induces MCP-1 secretion by pleural mesothelial cells","volume":"26","author":"Tanaka","year":"2000","journal-title":"Exp Lung Res."},{"key":"B14","first-page":"1144","article-title":"Participation of iron and nitric oxide in the mutagenicity of asbestos in hgprt-, gpt+ Chinese hamster V79 cells","volume":"58","author":"Park","year":"1998","journal-title":"Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"L471","DOI":"10.1152\/ajplung.1995.268.3.L471","article-title":"Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals","volume":"268","author":"Kamp","year":"1995","journal-title":"Am J Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1006\/abbi.1996.0059","article-title":"Participation of nitric oxide and iron in the oxidation of DNA in asbestos-treated human lung epithelial cells","volume":"326","author":"Chao","year":"1996","journal-title":"Arch Biochem Biophys."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1289\/ehp.97105s51257","article-title":"Pleural macrophage recruitment and activation in asbestos-induced pleural injury","volume":"105","author":"Choe","year":"1997","journal-title":"Environ Health Perspect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/ijms17030322","article-title":"Asbestos induces oxidative stress and activation of Nrf2 signaling in murine macrophages: chemopreventive role of the synthetic lignan secoisolariciresinol diglucoside (LGM2605)","volume":"17","author":"Pietrofesa","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B19","first-page":"6305","article-title":"Chrysotile fiber is a strong mutagen in mammalian cells","volume":"52","author":"Hei","year":"1992","journal-title":"Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbagen.2016.09.031","article-title":"Quantitative analysis of the role of fiber length on phagocytosis and inflammatory response by alveolar macrophages","volume":"1861","author":"Padmore","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj."},{"key":"B22","doi-asserted-by":"publisher","first-page":"10397","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/S0002-9440(10)65698-2","article-title":"TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers","volume":"153","author":"Liu","year":"1998","journal-title":"Am J Pathol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gueugnon","year":"2011","journal-title":"Am J Pathol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","article-title":"Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun."},{"key":"B28","first-page":"4376","article-title":"Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance","volume":"53","author":"Klominek","year":"1993","journal-title":"Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/(SICI)1097-0215(19970917)72:6<1034::AID-IJC19>3.0.CO;2-4","article-title":"Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins","volume":"72","author":"Klominek","year":"1997","journal-title":"Int J Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/thorax.58.3.198","article-title":"Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors","volume":"58","author":"Liu","year":"2003","journal-title":"Thorax."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e7016","DOI":"10.1371\/journal.pone.0007016","article-title":"Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target","volume":"4","author":"Crispi","year":"2009","journal-title":"PLoS ONE."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/sj.bjc.6600920","article-title":"Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura","volume":"88","author":"Edwards","year":"2003","journal-title":"Br J Cancer."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.ajpath.2011.05.060","article-title":"Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network","volume":"179","author":"Li","year":"2011","journal-title":"Am J Pathol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s42003-018-0137-0","article-title":"Origin of cancer-associated fibroblasts and tumor-associated macrophages in humans after sex-mismatched bone marrow transplantation","volume":"1","author":"Kurashige","year":"2018","journal-title":"Commun Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"8792","DOI":"10.1038\/ncomms9792","article-title":"Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab","volume":"6","author":"Mitsuhashi","year":"2015","journal-title":"Nat Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and\u22122, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","article-title":"Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy","volume":"190","author":"Schelch","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G","article-title":"Hepatocyte growth factor\/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor","volume":"76","author":"Klominek","year":"1998","journal-title":"Int J Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.04.007","article-title":"c-Met expression and MET amplification in malignant pleural mesothelioma","volume":"23","author":"Bois","year":"2016","journal-title":"Ann Diagn Pathol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/thx.2007.085241","article-title":"EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors","volume":"63","author":"Kothmaier","year":"2008","journal-title":"Thorax."},{"key":"B43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer."},{"key":"B44","doi-asserted-by":"publisher","first-page":"S1087","DOI":"10.1016\/j.jtho.2016.11.1519","article-title":"P2.06-026 A Phase II trial of the oral FGF receptor inhibitor AZD4547 as 2nd or 3rd line therapy in malignant pleural mesothelioma - trial in progress: topic: mesothelioma and SCLC","volume":"12","author":"Lam","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00783-7","article-title":"A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma","author":"van Brummelen","year":"2019","journal-title":"Invest New Drugs"},{"key":"B46","doi-asserted-by":"publisher","first-page":"32992","DOI":"10.1038\/srep32992","article-title":"PI3 Kinase pathway and MET inhibition is efficacious in malignant pleural mesothelioma","volume":"6","author":"Kanteti","year":"2016","journal-title":"Sci Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"10070","DOI":"10.1038\/s41598-018-28297-x","article-title":"Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo","volume":"8","author":"Li","year":"2018","journal-title":"Sci Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","article-title":"Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages","volume":"11","author":"Chene","year":"2016","journal-title":"J Thorac Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-17-3757","article-title":"Tumor-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients","volume":"24","author":"Khanna","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.chest.2016.01.001","article-title":"Longitudinal measurement of pleural fluid biochemistry and cytokines in malignant pleural effusions","volume":"149","author":"Thomas","year":"2016","journal-title":"Chest."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J Thorac Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/path.2829","article-title":"The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma","volume":"223","author":"Li","year":"2011","journal-title":"J Pathol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nrc2344","article-title":"Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability","volume":"8","author":"Bristow","year":"2008","journal-title":"Nat Rev Cancer."},{"key":"B55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lungcan.2015.07.015","article-title":"Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT","volume":"90","author":"Francis","year":"2015","journal-title":"Lung Cancer."},{"key":"B56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","article-title":"Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)","volume":"51","author":"Klabatsa","year":"2006","journal-title":"Lung Cancer."},{"key":"B57","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1186\/s12885-018-4720-z","article-title":"Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","article-title":"HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment","volume":"207","author":"Corzo","year":"2010","journal-title":"J Exp Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"7465","DOI":"10.1158\/0008-5472.CAN-10-1439","article-title":"Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression","volume":"70","author":"Doedens","year":"2010","journal-title":"Cancer Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1309\/AJCP5KNL7QTELLYI","article-title":"Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells","volume":"141","author":"Minato","year":"2014","journal-title":"Am J Clin Pathol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1245\/s10434-013-3077-4","article-title":"Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study","volume":"20","author":"Hommell-Fontaine","year":"2013","journal-title":"Ann Surg Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1164\/rccm.200811-1729OC","article-title":"Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions","volume":"180","author":"Davies","year":"2009","journal-title":"Am J Respir Crit Care Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4049\/jimmunol.1701041","article-title":"Metabolic barriers to T cell function in tumors","volume":"200","author":"Sugiura","year":"2018","journal-title":"J Immunol."},{"key":"B65","first-page":"4075","article-title":"L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma","volume":"31","author":"Kaira","year":"2011","journal-title":"Anticancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.18632\/oncotarget.2731","article-title":"Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma","volume":"6","author":"Salaroglio","year":"2015","journal-title":"Oncotarget."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology."},{"key":"B68","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1038\/s41388-018-0153-z","article-title":"How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations","volume":"37","author":"Rehrauer","year":"2018","journal-title":"Oncogene."},{"key":"B71","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/JTO.0b013e31824c9272","article-title":"CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions","volume":"7","author":"Blanquart","year":"2012","journal-title":"J Thorac Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1309\/LN2075V7C8K31CH8","article-title":"Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells","volume":"127","author":"Davidson","year":"2007","journal-title":"Am J Clin Pathol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1167","DOI":"10.1038\/cddis.2014.136","article-title":"Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation","volume":"5","author":"Cioce","year":"2014","journal-title":"Cell Death Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","article-title":"Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma","volume":"4","author":"DeLong","year":"2005","journal-title":"Cancer Biol Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2249.1994.tb06144.x","article-title":"Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer","volume":"98","author":"Maeda","year":"1994","journal-title":"Clin Exp Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1084\/jem.20111653","article-title":"TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth","volume":"209","author":"Fujii","year":"2012","journal-title":"J Exp Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e1373235","DOI":"10.1080\/2162402X.2017.1373235","article-title":"The \u201cdon't eat me\u201d signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma","volume":"7","author":"Schurch","year":"2017","journal-title":"Oncoimmunology."},{"key":"B78","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3892\/ijo_00000180","article-title":"Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages","volume":"34","author":"Izzi","year":"2009","journal-title":"Int J Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1158\/1535-7163.MCT-07-0579","article-title":"Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma","volume":"7","author":"Miselis","year":"2008","journal-title":"Mol Cancer Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br J Cancer."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e106742","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PLoS ONE."},{"key":"B82","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s12199-016-0530-6","article-title":"Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma","volume":"21","author":"Tanrikulu","year":"2016","journal-title":"Environ Health Prev Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e104848","DOI":"10.1371\/journal.pone.0104848","article-title":"Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area","volume":"9","author":"Comar","year":"2014","journal-title":"PLoS ONE."},{"key":"B85","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet."},{"key":"B86","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e1278330","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"Oncoimmunology."},{"key":"B88","doi-asserted-by":"publisher","first-page":"89722","DOI":"10.18632\/oncotarget.21113","article-title":"Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients","volume":"8","author":"Marcq","year":"2017","journal-title":"Oncotarget."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS ONE."},{"key":"B90","doi-asserted-by":"publisher","first-page":"20769","DOI":"10.18632\/oncotarget.25100","article-title":"Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma","volume":"9","author":"Watanabe","year":"2018","journal-title":"Oncotarget."},{"key":"B91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28\u20138 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"BMJ."},{"key":"B93","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1601482","DOI":"10.1080\/2162402X.2019.1601482","article-title":"Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion","volume":"8","author":"Bertino","year":"2019","journal-title":"OncoImmunology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"111ra20","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci Transl Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother."},{"key":"B97","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1510\/icvts.2009.223255","article-title":"Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?","volume":"10","author":"Lucchi","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"B98","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbrc.2006.03.018","article-title":"Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy","volume":"343","author":"Needham","year":"2006","journal-title":"Biochem Biophys Res Commun."},{"key":"B99","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1183\/09031936.00101008","article-title":"Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells","volume":"34","author":"Jackaman","year":"2009","journal-title":"Eur Respir J."},{"key":"B100","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"CT036","DOI":"10.1158\/1538-7445.SABCS18-CT036","article-title":"Abstract CT036: a phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy","volume":"79","author":"Adusumilli","year":"2019","journal-title":"AACR."},{"key":"B102","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J Transl Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest."},{"key":"B105","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun."},{"key":"B109","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat Med."},{"key":"B110","first-page":"4756","article-title":"Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients","volume":"61","author":"Schmielau","year":"2001","journal-title":"Cancer Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.bjc.6600673","article-title":"Chemotherapy for malignant pleural mesothelioma: past results and recent developments","volume":"88","author":"Tomek","year":"2003","journal-title":"Br J Cancer."},{"key":"B113","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0169-5002(98)00014-2","article-title":"Sera from patients with malignant mesothelioma can contain autoantibodies","volume":"20","author":"Robinson","year":"1998","journal-title":"Lung Cancer."},{"key":"B114","article-title":"Mesothelioma and tumor-associated autoantibodies. D31 Non-pulmonary critical care and monitoring","volume-title":"American Thoracic Society International Conference Abstracts: American Thoracic Society.","author":"Chapman","year":"2011"},{"key":"B115","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41416-018-0313-5","article-title":"VISTA expressed in tumour cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"Br J Cancer."},{"key":"B116","doi-asserted-by":"publisher","first-page":"5804230","DOI":"10.1155\/2018\/5804230","article-title":"Complex immune contextures characterise malignant peritoneal mesothelioma: loss of adaptive immunological signature in the more aggressive histological types","volume":"2018","author":"Tazzari","year":"2018","journal-title":"J Immunol Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2438598","DOI":"10.1155\/2018\/2438598","article-title":"Natural killer cells from malignant pleural effusion are endowed with a decidual-like proangiogenic polarization","volume":"2018","author":"Bosi","year":"2018","journal-title":"J Immunol Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/1471-2407-13-324","article-title":"Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid","volume":"13","author":"Scherpereel","year":"2013","journal-title":"BMC Cancer."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/ijc.32363","article-title":"NK- and T-cell subsets in malignant mesothelioma patients: baseline pattern and changes in the context of anti-CTLA-4 therapy","volume":"145","author":"Sottile","year":"2019","journal-title":"Int J Cancer"},{"key":"B120","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/eji.201242783","article-title":"NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation","volume":"43","author":"Vacca","year":"2013","journal-title":"Eur J Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/intimm\/dxs005","article-title":"IL-2\/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector\/memory phase","volume":"24","author":"Jackaman","year":"2012","journal-title":"Int Immunol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/JTO.0b013e3181989ddb","article-title":"Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor","volume":"4","author":"Ali","year":"2009","journal-title":"J Thorac Oncol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","article-title":"The parallel lives of angiogenesis and immunosuppression: cancer and other tales","volume":"11","author":"Motz","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B124","first-page":"1857","article-title":"Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma","volume":"8","author":"Edwards","year":"2002","journal-title":"Clin Cancer Res."},{"key":"B125","doi-asserted-by":"publisher","first-page":"21783","DOI":"10.18632\/oncotarget.25004","article-title":"Targeting Tie-2\/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications","volume":"9","author":"Magkouta","year":"2018","journal-title":"Oncotarget."},{"key":"B126","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat Rev Cancer."},{"key":"B127","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature."},{"key":"B128","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br J Cancer."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01366\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T04:43:36Z","timestamp":1575607416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01366\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":128,"alternative-id":["10.3389\/fonc.2019.01366"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01366","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]},"article-number":"1366"}}